Champions Oncology, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Champions Oncology, Inc.
As predicted by Scrip last July, WuXi AppTec has moved one step closer to spinning out its biologics unit through an IPO on the Hong Kong equity market, while its main business unit is also proceeding with plans for a China domestic relisting.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced March 2015.
Champions Oncology has developed TumorGraft, a novel predictive chemo-response technology that allows companies to simulate clinical trials, test anticancer drug regimens, and identify the regimens most likely to positively impact individual cancer tumors. For the clinical trial simulation capabilities alone, the technology has a market potential of $1.6 billion in the US, according to the company.
Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.
- Drug Discovery Tools
- Large Molecule
Drug Discovery Tools
- Other Names / Subsidiaries
- Champions Biotechnology, Inc.
- Champions Oncology, Ltd.